GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (FRA:6L8) » Definitions » Stock Based Compensation

Pulse Biosciences (FRA:6L8) Stock Based Compensation : €7.42 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Pulse Biosciences Stock Based Compensation?

Pulse Biosciences's Stock Based Compensation for the three months ended in Mar. 2024 was €1.62 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was €7.42 Mil.


Pulse Biosciences Stock Based Compensation Historical Data

The historical data trend for Pulse Biosciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Stock Based Compensation Chart

Pulse Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.16 8.29 12.92 4.90 6.58

Pulse Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 1.05 1.69 3.06 1.62

Pulse Biosciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.42 Mil.


Pulse Biosciences Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (FRA:6L8) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Pulse Biosciences (FRA:6L8) Headlines

No Headlines